Ratings Merck KGaA Wiener Boerse

Equities

MRCK

DE0006599905

Real-time Estimate Tradegate Other stock markets 06:21:25 24/06/2024 pm IST			5-day change	1st Jan Change
165.2 ^EUR	+0.89%		-4.82%	+14.59%

18/06	Economics Minister Habeck travels to China without prominent company representatives	RE
18/06	German economy minister's China trip features low-key business delegation amid EV clash	RE

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The firm trades with high earnings multiples: 24.24 times its 2024 earnings per share.
With an enterprise value anticipated at 3.69 times the sales for the current fiscal year, the company turns out to be overvalued.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MERCK KGAA	+14.59%	77.46B		-
KYOWA KIRIN CO. LTD.	+13.86%	8.94B		A-
SK BIOPHARMACEUTICALS CO., LTD.	-24.30%	4.28B		A-
YUHAN CORPORATION	+12.79%	4.18B		B-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+31.45%	4.11B		-
INDIVIOR PLC	+9.20%	2.23B		B
BETTA PHARMACEUTICALS CO., LTD.	-30.57%	2.06B		C-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.99%	1.97B	-	-
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-45.76%	1.69B		-
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes